A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial
Chikungunya virus (CHIKV) is a reemerging mosquito-borne virus that causes swift outbreaks. Major concerns are the persistent and disabling polyarthralgia in infected individuals. Here we present the results from a first-in-human trial of the candidate simian adenovirus vectored vaccine ChAdOx1 Chik...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Springer Nature
2021
|
| _version_ | 1797063150998126592 |
|---|---|
| author | Folegatti, P Harrison, K Preciado-Llanes, L Ramos Lopez, F Bittaye, M Kim, Y Flaxman, A Bellamy, D Makinson, R Sheridan, J Tilley, M Tran, N Jenkin, D Poulton, I Lawrie, A Roberts, R Berrie, E Hill, A Ewer, K Reyes-Sandoval, A |
| author_facet | Folegatti, P Harrison, K Preciado-Llanes, L Ramos Lopez, F Bittaye, M Kim, Y Flaxman, A Bellamy, D Makinson, R Sheridan, J Tilley, M Tran, N Jenkin, D Poulton, I Lawrie, A Roberts, R Berrie, E Hill, A Ewer, K Reyes-Sandoval, A |
| author_sort | Folegatti, P |
| collection | OXFORD |
| description | Chikungunya virus (CHIKV) is a reemerging mosquito-borne virus that causes swift outbreaks. Major concerns are the persistent and disabling polyarthralgia in infected individuals.
Here we present the results from a first-in-human trial of the candidate simian adenovirus
vectored vaccine ChAdOx1 Chik, expressing the CHIKV full-length structural polyprotein
(Capsid, E3, E2, 6k and E1). 24 adult healthy volunteers aged 18–50 years, were recruited in a
dose escalation, open-label, nonrandomized and uncontrolled phase 1 trial (registry
NCT03590392). Participants received a single intramuscular injection of ChAdOx1 Chik at
one of the three preestablished dosages and were followed-up for 6 months. The primary
objective was to assess safety and tolerability of ChAdOx1 Chik. The secondary objective was
to assess the humoral and cellular immunogenicity. ChAdOx1 Chik was safe at all doses
tested with no serious adverse reactions reported. The vast majority of solicited adverse
events were mild or moderate, and self-limiting in nature. A single dose induced IgG and Tcell responses against the CHIKV structural antigens. Broadly neutralizing antibodies against
the four CHIKV lineages were found in all participants and as early as 2 weeks after vaccination. In summary, ChAdOx1 Chik showed excellent safety, tolerability and 100% PRNT50
seroconversion after a single dose. |
| first_indexed | 2024-03-06T20:55:43Z |
| format | Journal article |
| id | oxford-uuid:392ef680-ccfc-4eee-a066-312181e544c7 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:55:43Z |
| publishDate | 2021 |
| publisher | Springer Nature |
| record_format | dspace |
| spelling | oxford-uuid:392ef680-ccfc-4eee-a066-312181e544c72022-03-26T13:54:06ZA single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:392ef680-ccfc-4eee-a066-312181e544c7EnglishSymplectic ElementsSpringer Nature2021Folegatti, PHarrison, KPreciado-Llanes, LRamos Lopez, FBittaye, MKim, YFlaxman, ABellamy, DMakinson, RSheridan, JTilley, MTran, NJenkin, DPoulton, ILawrie, ARoberts, RBerrie, EHill, AEwer, KReyes-Sandoval, AChikungunya virus (CHIKV) is a reemerging mosquito-borne virus that causes swift outbreaks. Major concerns are the persistent and disabling polyarthralgia in infected individuals. Here we present the results from a first-in-human trial of the candidate simian adenovirus vectored vaccine ChAdOx1 Chik, expressing the CHIKV full-length structural polyprotein (Capsid, E3, E2, 6k and E1). 24 adult healthy volunteers aged 18–50 years, were recruited in a dose escalation, open-label, nonrandomized and uncontrolled phase 1 trial (registry NCT03590392). Participants received a single intramuscular injection of ChAdOx1 Chik at one of the three preestablished dosages and were followed-up for 6 months. The primary objective was to assess safety and tolerability of ChAdOx1 Chik. The secondary objective was to assess the humoral and cellular immunogenicity. ChAdOx1 Chik was safe at all doses tested with no serious adverse reactions reported. The vast majority of solicited adverse events were mild or moderate, and self-limiting in nature. A single dose induced IgG and Tcell responses against the CHIKV structural antigens. Broadly neutralizing antibodies against the four CHIKV lineages were found in all participants and as early as 2 weeks after vaccination. In summary, ChAdOx1 Chik showed excellent safety, tolerability and 100% PRNT50 seroconversion after a single dose. |
| spellingShingle | Folegatti, P Harrison, K Preciado-Llanes, L Ramos Lopez, F Bittaye, M Kim, Y Flaxman, A Bellamy, D Makinson, R Sheridan, J Tilley, M Tran, N Jenkin, D Poulton, I Lawrie, A Roberts, R Berrie, E Hill, A Ewer, K Reyes-Sandoval, A A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial |
| title | A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial |
| title_full | A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial |
| title_fullStr | A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial |
| title_full_unstemmed | A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial |
| title_short | A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial |
| title_sort | single dose of chadox1 chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial |
| work_keys_str_mv | AT folegattip asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT harrisonk asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT preciadollanesl asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT ramoslopezf asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT bittayem asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT kimy asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT flaxmana asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT bellamyd asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT makinsonr asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT sheridanj asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT tilleym asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT trann asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT jenkind asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT poultoni asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT lawriea asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT robertsr asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT berriee asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT hilla asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT ewerk asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT reyessandovala asingledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT folegattip singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT harrisonk singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT preciadollanesl singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT ramoslopezf singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT bittayem singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT kimy singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT flaxmana singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT bellamyd singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT makinsonr singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT sheridanj singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT tilleym singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT trann singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT jenkind singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT poultoni singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT lawriea singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT robertsr singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT berriee singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT hilla singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT ewerk singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial AT reyessandovala singledoseofchadox1chikvaccineinducesneutralisingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial |